About this episode

An interview with Byoung Chul Cho MD PhD discussing the promising responses of a new KRAS G12C inhibitor in advanced lung cancer patients.

New Generation KRAS G12C Inhibitor Brings Promising Responses Even in Patients with Advanced Lung Cancers Refractory to Previous KRAS-targeted Therapy An interview with Byoung Chul Cho MD PhD, Thoracic Medical Oncologist, Professor, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. SAN DIEGO, USA—In a phase 1/2 study in which patients with advanced non-small cell lung cancer were treated with the next-generation KRAS-G12C inhibitor elisrasib, responses were seen not only in patients who were not treated with prior KRAS G12C inhibitors but also in those whose disease progressed on prior KRAS G12C inhibitors. Study findings were reported at the 2026 Annual Meeting of the American Association for Cancer Research by Byoung Chul Cho MD PhD, a professor and thoracic medical oncologist at the Yonsei Cancer Center, in Yonsei University College of Medicine, Seoul, South Korea. He discussed his findings with our reporter Peter Goodwin. PODCAST: Byoung Chul Cho MD PhD IN: [GOODWIN]”I’m here at the American OUT:…….for Cancer Research. I’m Peter Goodwin 7:58secs AACR 2026 abstract: Session Type: Clinical Trials Plenary Session Session Title: New Frontiers in…

More episodes of Audio Journal of Oncology Podcast

• Jonathan Wesley Riess MD; 2026 AACR: Investigational KRAS(ON) Inhibitor Zoldonrasib Showed Effective and Durable Responses in Patients With Advanced G12D-mutated Lung Cancer · May 6, 2026 · 8 min
• Tao Zhu MD; AACR 2026: Anti-Claudin 6 Antibody Drug Conjugate Benefits Patients with Advanced Platinum-Resistant Ovarian Cancer with Low Toxicity · April 28, 2026 · 5 min
• Moran Amit MD PhD; AACR 2026: Oral Intralesional PD 1 Blockade Promises Less Risk of Progression to Oral Cancer than Surgery, with Preserved Quality of Life · April 27, 2026 · 10 min
• Elena Garralda MD PhD, AACR 2026: Molecular Glue Degrader Improves Outcomes in Heavily Pre-treated Patients with Advanced Solid Tumors · April 23, 2026 · 9 min
• Icro Meattini MD; 2026 EBCC: Safe to Avoid Endocrine Therapy in Older Women with Low Risk Breast Cancers: EUROPA Study Interim Findings · April 16, 2026 · 5 min
• Amparo Garcia-Tejedor MD, PhD; 2026 EBCC: Axillary Radiotherapy Seems As Effective as Axillary Lymphadenectomy in Sentinel Node Positive Early Breast Cancer, with Less Risk of Lymphedema · April 13, 2026 · 7 min

Explore listener stats, chart rankings, contacts and more on the Audio Journal of Oncology Podcast podcast page.